Physician profile
Mark Alan Briel
NPI 1417946500
$285.31
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $20.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $67.54 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.83 | 2019-2020 | |
| Minerva Surgical, INC | $31.23 | 2019 | |
| Amag Pharmaceuticals, INC. | $21.21 | 2019 | |
| Daiichi Sankyo INC. | $18.09 | 2019 | |
| Smith+Nephew, INC. | $16.83 | 2019 | |
| Mylan Pharmaceuticals INC. | $15.40 | 2019 | |
| Therapeuticsmd, INC. | $14.24 | 2019 | |
| Boston Scientific Corporation | $13.64 | 2019 | |
| Merck Sharp & Dohme LLC | $11.80 | 2019 | |
| Lupin INC. | $11.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Briel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.